1-6 of 6
Mina Shahkarami
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

BRAVE: A Phase 2 Trial Evaluating the Efficacy and Safety of Venetoclax in Combination with Bruton's Tyrosine Kinase Inhibitors in Patients with First-Line Chronic Lymphocytic Leukemia

Matthew S. Davids, John M. Burke, Jennifer A. Woyach, Mina Shahkarami, Katherine Eakle, Jinnie Ko, Vivek S. Chopra, Weize Huang, Rona Farighi, Richard H. Ko, Jeff P. Sharman, William G. Wierda
Journal: Blood
Blood (2024) 144 (Supplement 1): 3257.2.
https://doi.org/10.1182/blood-2024-201555
Published: 2024
Journal Articles

Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)

Jacob D. Soumerai, Ahmet Dogan, Venkatraman Seshan, Kelsey Leigh Flaherty, Natalie Slupe, Jason Carter, Ephraim Hochberg, Jeffrey A. Barnes, Jeremy S. Abramson, Audrey Hamilton, Ariela Noy, Colette Owens, Maria Lia Palomba, Anita Kumar, Lindsey Roeker, Meghan C. Thompson, Ronald W. Takvorian, Zachary D. Epstein-Peterson, Mark Blaine Geyer, Gilles Salles, Robert Stuver, Philip Caron, Prioty Islam, Tamanna Haque, Paola Ghione, Raphael E. Steiner, Pallawi Torka, Kevin A. David, Jennifer Kimberly Lue, Paul A. Hamlin, Alison Moskowitz, Lorenzo Falchi, Julie Haydu, Patrick Connor Johnson, Joanna Mi, Jessica Pendleton, Alyssa Labarre, Rosalba Martignetti, Sean F. Plummer, Maria Chabowska, Walter Ramos Amador, Neena Mahajan, Morgan Choma, Clare Grieve, Rayna N. Garcia, Hailey E. Kelly, Ella Mallinger, James O'Grady, Bernadette Beatty, Michelle Adams, Athina Apazidis, Aileen Cleary Cohen, Mina Shahkarami, Allison P. Jacob, Omar Abdel-Wahab, Andrew D. Zelenetz
Journal: Blood
Blood (2024) 144 (Supplement 1): 1867.
https://doi.org/10.1182/blood-2024-205697
Published: 2024
Journal Articles

Best Practices to Overcoming Challenges in Initiating Venetoclax for Patients with Chronic Lymphocytic Leukemia: Results from a United States Community-Based Healthcare Practitioner Survey

Ryan Jacobs, Luke Fletcher, Andrew Rettew, Sophia S Li, Katherine Eakle, Mina Shahkarami, Rongrong Wang, Tu My To, Susan D Mathias, Isabella Manigault, John M. Burke
Journal: Blood
Blood (2024) 144 (Supplement 1): 2268.
https://doi.org/10.1182/blood-2024-198466
Published: 2024
Journal Articles

Contribution of Obinutuzumab to Acalabrutinib Therapy in Patients with Treatment-Naive Chronic Lymphocytic Leukemia: Analysis of Survival Outcomes By Genomic Features

Matthew S. Davids, Jeff P. Sharman, Toby A. Eyre, Jennifer A. Woyach, Paulo Andre P. de Miranda, Mina Shahkarami, Anna Butturini, Ugochinyere Emeribe, John C. Byrd
Journal: Blood
Blood (2022) 140 (Supplement 1): 4173–4175.
https://doi.org/10.1182/blood-2022-157018
Published: 2022
Journal Articles

Clinician and Patient Factors Influencing Treatment Decisions in Front-Line Chronic Lymphocytic Leukemia: A Qualitative Research Study

Michael Wallington, Xavier Guillaume, Emily Mulvihill, Graceanne R Wayser, Vandana Kaul, Claire Graziani-Taugeron, Mina Shahkarami, Kellie J. Ryan
Journal: Blood
Blood (2022) 140 (Supplement 1): 10810–10811.
https://doi.org/10.1182/blood-2022-165766
Published: 2022
Journal Articles

Majic: A Phase 3 Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Matthew S. Davids, Anthony R. Mato, Juliette Hum, Susana Wargo, Ugochinyere Emeribe, Mina Shahkarami, Kevin Sokolowski, Juliana M.L. Biondo, Sarang Abhyankar, Rick Hermann, Jeff P. Sharman
Journal: Blood
Blood (2021) 138 (Supplement 1): 1553.
https://doi.org/10.1182/blood-2021-148155
Published: 2021